Shanghai Pulmonary Hospital

Running trials

• Not yet recruiting

  A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

  NCT05745740· Phase 1/2· RemeGen Co., Ltd.· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Boehringer Ingelheim· Source

• Not yet recruiting

  Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07912268· Phase 1· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

• Recruiting

  Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC

  NCT07874581· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)

  NCT07830342· Phase 1· Hangzhou Huasai Biomedicine Co., Ltd.· Source

• Recruiting

  Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer

  NCT07806604· Betta Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

  NCT07778316· Phase 3· Amgen· Source

• Not yet recruiting

  The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer

  NCT07704645· Phase 2· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source

• Recruiting

  T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD

  NCT07823842· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

  NCT07672223· Phase 3· CSPC Megalith Biopharmaceutical Co.,Ltd.· Source

• Recruiting

  A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  NCT07586202· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

  NCT07642024· Phase 2/3· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD

  NCT07665359· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC

  NCT07754812· Phase 4· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

  NCT07653958· Peking Union Medical College Hospital· Source

• Not yet recruiting

  A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

  NCT07550842· Phase 1· Shanghai Best-Link Bioscience, LLC· Source

• Not yet recruiting

  Application of Electromagnetic Navigation System in Pulmonary Nodule Localization

  NCT07595120· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC

  NCT07863999· Phase 3· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

  NCT07593027· Phase 1/2· ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.· Source

• Not yet recruiting

  A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

  NCT07469488· Phase 4· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

  NCT07308106· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

  NCT07416474· Phase 3· RemeGen Co., Ltd.· Source

• Not yet recruiting

  Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

  NCT07517640· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Phase II Study of RC1416 Injection in COPD

  NCT07402551· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source

• Not yet recruiting

  Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

  NCT07493980· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

  NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

  NCT07393438· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Not yet recruiting

  A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

  NCT07375979· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

  NCT07269782· Phase 2· Shanghai Henlius Biotech· Source

• Recruiting

  First in Human Study of SIM0610 in Solid Tumors

  NCT07348211· Phase 1· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

  NCT07410975· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  NCT07820254· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

  NCT07408635· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

  NCT07323056· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· Phase 2/3· AbbVie· Source

• Recruiting

  Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

  NCT07243873· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

  NCT07182682· Phase 3· Dizal (Jiangsu) Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

  NCT07217301· Phase 3· Takeda· Source

• Recruiting

  A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

  NCT07155174· Phase 2· AbbVie· Source

• Recruiting

  Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

  NCT07742332· Phase 2· Peng Zhang· Source

• Active, not recruiting

  Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

  NCT07162883· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

  NCT07121413· Phase 2· Shanghai Synvida Biotechnology Co.,Ltd.· Source

• Active, not recruiting

  A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

  NCT07245407· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 164.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer93 recruiting
• Bronchiectasis4 recruiting
• COPD4 recruiting
• High blood pressure3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Asthma2 recruiting
• Colorectal cancer2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Tuberculosis2 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Completed

  A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

  NCT07252908· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

  NCT07807007· Phase 2· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  Impact of Different Lung Isolation Devices on Pharyngolaryngeal Injuries After Pulmonary Resection

  NCT07117539· Tingting Li· Source

• Terminated

  Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

  NCT06924606· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Withdrawn

  Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

  NCT06895941· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Completed

  Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

  NCT06648200· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

  NCT06498479· Phase 3· Hansoh BioMedical R&D Company· Source

• Completed

  Budesonide/Formoterol Inhalation Powder in Adults With Asthma

  NCT07790159· Phase 3· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD

  NCT06643078· Phase 3· Haisco Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Withdrawn

  A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

  NCT05212922· Phase 2· Eucure (Beijing) Biopharma Co., Ltd· Source

• Completed

  A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

  NCT05895565· Phase 1· Pulmongene Ltd.· Source

• Completed

  CX3CR1+T Cell Predict Immunotherapy Efficacy

  NCT06054152· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Completed

  Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

  NCT05577702· Phase 2· BeiGene· Source

• Completed

  Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

  NCT05815862· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

  NCT05635708· Phase 2· BeiGene· Source

• Completed

  A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

  NCT05519865· Phase 2· Chipscreen Biosciences, Ltd.· Source

• Terminated

  A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

  NCT05662670· Phase 1/2· Suzhou Junjing BioSciences Co., Ltd.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

  NCT05918107· Phase 2· Biotheus Inc.· Source

• Completed

  Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05014815· Phase 2· BeiGene· Source

• Terminated

  AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

  NCT04993391· Phase 1/2· Suzhou Junjing BioSciences Co., Ltd.· Source

• Completed

  A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

  NCT04900363· Phase 1/2· Akeso· Source

• Completed

  A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB

  NCT05278988· Phase 4· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Completed

  Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

  NCT04702009· Phase 2/3· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Completed

  Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

  NCT04622228· Phase 2· Hoffmann-La Roche· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

  NCT04194203· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer

  NCT07121387· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

  NCT04716933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Actelion· Source

• Completed

  Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04005716· Phase 3· BeiGene· Source

• Completed

  Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

  NCT03924050· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Ariad Pharmaceuticals· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

  NCT03789604· Phase 3· CStone Pharmaceuticals· Source

• Completed

  Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03358875· Phase 3· BeiGene· Source

• Completed

  A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  NCT02716116· Phase 1/2· Takeda· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

  NCT02075840· Phase 3· Hoffmann-La Roche· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer284 works · 168 trials
• Tuberculosis46 works · 2 trials
• Bronchiectasis20 works · 5 trials
• Idiopathic pulmonary fibrosis19 works · 6 trials
• Pulmonary arterial hypertension15 works · 10 trials